37 results about "Neuroblastoma cell" patented technology

The invention discloses 9-phenyl-10-aryloxy evodiamine quinazolinone with a structural formula shown as a formula 3, wherein Ar is selected from benzyl and substituted benzyl. The invention further discloses a preparation method of the 9-phenyl-10-aryloxy evodiamine quinazolinone. The 9-phenyl-10-aryloxy evodiamine quinazolinone derivative as shown in the formula 3 is prepared by the following steps: (1) taking 10-hydroxyevodiamine (A) as a raw material, and reacting with an arylation reagent (ArX) in the presence of a proper alkali catalyst under proper conditions to obtain 10-aryloxy evodiamine 1; (2) reacting the compound 1 with a bromination reagent under proper conditions to obtain 9-bromo-10-aryloxy evodiamine 2; and (3) reacting the compound 2 with an arylboronic acid reagent under proper conditions to obtain the 9-phenyl-10-aryloxy evodiamine quinazolinone derivative 3. The 9-phenyl-10-aryloxy evodiamine quinazolinone derivative 3 synthesized by the preparation method disclosed by the invention is used for treating liver cancer cells in vitro; the neuroblastoma cells show good anti-cancer activity and can be applied to preparation of corresponding anti-tumor drugs.

This invention relates to the field of pharmaceutical technology, specifically the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis. Using human neuroblastoma cells (SH-SY5Y) as target cells, this invention utilizes activators from a library of ubiquitinated compounds to target and activate key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This helps to understand the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention experimentally discovered that NEDD8 activator (NAE) has the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of NEDD8 activator in the preparation of drugs for treating Japanese encephalitis, offering new targets and treatment strategies for the prevention and treatment of JEV.

The invention belongs to the technical field of biological medicines, and particularly relates to application of cardiac glycoside medicines or pharmaceutically acceptable salts or derivatives thereof in preparation of products for inhibition, relief, adjuvant therapy or treatment of cancers and medicines. The invention provides application of cardiac glycoside drugs or pharmaceutically acceptable salts or derivatives of the cardiac glycoside drugs in preparation of products for inhibition, alleviation, adjuvant therapy or treatment of cancers and the drugs, and the cardiac glycoside drugs comprise deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside, deacetylated chaenoside and deacetylated chaenoside. According to the application disclosed by the invention, the effects of inhibiting, relieving, assisting in treating or treating cancers and potential mechanisms of the Deslanoside are researched in SH-SY5Y and SK-N-SH neuroblastoma cell lines, and results show that the Deslanoside can be used for inhibiting proliferation of SH-SY5Y cells and SK-N-SH cells, promoting apoptosis and respectively inducing a cell cycle to stop at a G0 / G1 phase; and G1 / S and G2 / M periods.

The invention discloses a novel amide compound with a substituted diphenyl ether structure as well as a preparation method and application of the novel amide compound. The compound comprises a structure as shown in a general formula (I) or a general formula (II), and is characterized in that a benzo five-membered aromatic heterocycle (including but not limited to benzofuran, benzothiophene, indole and the like) is connected with a substituted diphenyl ether group through an amido bond to form a unique molecular skeleton. Diversified substituent groups R1 such as halogen, alkyl and heterocyclic rings can be introduced into a benzene ring, substituent groups R2 such as alkyl and alkoxy (n is an integer from 0 to 2) are introduced into an intermediate connecting chain, and therefore diversity optimization of the molecular structure is achieved. A biological activity test shows that the compound has remarkable proliferation inhibition activity on SK-N-AS neuroblastoma cells, and shows potential treatment value on malignant tumors such as neuroblastoma. Through systematic molecular design, a substituted diphenyl ether structure compound with a novel structure is constructed, and a brand new chemical entity is provided for developing new anti-cancer drugs.

The application discloses an intervention strategy for targeting CACNA2D2 protein and application thereof, and belongs to the technical field of medicine and biotechnology.The application discloses for the first time that abnormal high expression of CACNA2D2 is related to poor prognosis of neuroblastoma, especially malignant progression, and provides that CACNA2D2 gene is used as a drug target to prepare a drug for treating neuroblastoma, and further provides application of CACNA2D2 siRNA in preparation of a drug for treating neuroblastoma.After down-regulation of CACNA2D2 gene expression, cell proliferation and clone formation ability of neuroblastoma cells are significantly inhibited.Therefore, the application provides a new direction for development of a drug for treating neuroblastoma, and provides a possibility for preparing a new drug for treating neuroblastoma, improving curative effect of patients, improving prognosis and survival.

The invention discloses probiotic fermented litchi juice as well as a preparation method and application thereof, and relates to the technical field of probiotic fermentation. The probiotic fermented litchi juice disclosed by the invention is prepared by taking fresh litchis as a raw material and fermenting the fresh litchis by using lactobacillus mucilaginosus NCU326. The invention also provides application of the probiotic fermented litchi juice in preparation of drugs for preventing and / or improving nerve injury. The probiotic fermented litchi juice disclosed by the invention is excellent in flavor, coordinated in nutrition, unique in fermentation flavor, soft in sourness and pleasant in fragrance (a lot of olefinic terpenoids and aldehyde compounds are degraded, and the contents of alcohol, ketone, ether and acid compounds are obviously increased), and the litchi beverage fermented by NCU326 is rich in nutrients, rich in nutrients, rich in nutrients, rich in nutrients, rich in nutrients, rich in nutrients, and rich in nutrition. The survival rate of human neuroblastoma SH-SY5Y cells damaged by 1-methyl-4-phenylpyridine ions (MPP +) can be remarkably increased, and the compound has certain potential in the aspect of improving nerve injury, so that the compound can be used for preparing the medicine for preventing and / or improving nerve injury.

The invention discloses 9-phenyl-10-cyclopropyl methoxy evodiamine quinazolinone with a structural formula as shown in a formula 3, and 9-phenyl-10-cyclopropyl methoxy evodiamine quinazolinone derivatives as shown in the formula 3. The preparation method comprises the following steps: (1) taking 10-hydroxy evodiamine (A) as a raw material; reacting with bromomethyl cyclopropane in the presence of a proper alkali catalyst under proper conditions to obtain 10-cyclopropyl methoxy evodiamine 1; (2) reacting the compound 1 with a bromination reagent under proper conditions to obtain 9-bromo-10-cyclopropyl methoxy evodiamine 2; and (3) reacting the compound 2 with an arylboronic acid reagent under proper conditions to obtain the 9-phenyl-10-cyclopropyl methoxy evodiamine quinazolinone derivative 3. The 9-phenyl-10-cyclopropyl methoxyl evodiamine quinazolinone derivative synthesized by the invention has the advantages that the 9-phenyl-10-cyclopropyl methoxyl evodiamine quinazolinone derivative is used for treating liver cancer cells in vitro; the neuroblastoma cells show good anti-cancer activity and can be applied to preparation of corresponding anti-tumor drugs.

According to the application of the salidroside in preparation of the medicine for treating the Alzheimer's disease by relieving ferroptosis, the salidroside is used for relieving the ferroptosis of human neuroblastoma (SH-SY 5Y) cells induced by A [beta] 1-42 by inhibiting a voltage dependent anion channel 1 (VDAC1) and activating an AKT / GSK-3beta pathway, and the application of the salidroside in the preparation of the medicine for treating the Alzheimer's disease by relieving the ferroptosis of the human neuroblastoma (SH-SY 5Y) is realized by inhibiting the voltage dependent anion channel 1 (VDAC1) and activating the AKT / GSK-3beta pathway. The salidroside can relieve the ferroptosis of SH-SY 5 Y cells induced by A beta 1-42 under the optimal concentration of 30 mM. After salidroside treatment, the expression quantity of GPX 4 and FTH 1 is increased, and the expression quantity of IREB 2 is reduced. The cell apoptosis rate is reduced, and the Fe < 2 + > content and ROS level in cells are also reduced. After si-VDAC 1 is transfected, the change trend of si-VDAC 1 is similar to the trend after salidroside treatment. In addition, the treatment of an AKT inhibitor and an AKT activator shows that an AKT / GSK-3beta signal channel participates in the process of inducing the ferroptosis of the SH-SY 5 Y cells by the Abeta1-42.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human neuroblastoma cells (SH-SY5Y) and human brain astroblastoma cells (U87) are taken as target cells, and the expression of the target cell part capable of exerting receptor action membrane protein is down-regulated by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting CHIKV infection of human nerve cells is found, and the purpose of blocking CHIKV infection from the source is achieved. It is found that platelet membrane glycoprotein VI (GP6) plays an important role in CHIKV infection SH-SY5Y and U87 cells, expression of GP6 is reduced, and CHIKV infection can be obviously inhibited. The invention provides an application of GP6 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, joint swelling, muscle pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The invention discloses a method for stereoselectively synthesizing a chiral triarylmethane thioether compound with antitumor biological activity, and relates to the technical field of medicine synthesis. According to the invention, a seven-membered ring system 3-indolyl [1, 4] sulfur azacycloheptane compound is used as a raw material, an asymmetric Friedel-Crafts alkylation reaction with nucleophilic indole is realized through a new strategy that a spiro chiral phosphonic acid catalyst catalyzes bond breaking of a carbon-nitrogen bond, a high-quality path is provided for synthesis of a chiral triarylmethane thioether compound, and the chiral triarylmethane thioether compound has a wide application prospect. Meanwhile, the reaction has the characteristics of easily available raw materials and mild conditions, and also has the technical advantages of high enantioselectivity and high atom economy. The chiral triarylmethane thioether compound provided by the invention has an obvious inhibition effect on the growth of human cervical cancer cells (HeLa), pancreatic cancer cells (Panc-1) and human bone marrow neuroblastoma cells (Sy5Y), shows good anti-tumor biological activity, and has important positive significance for promoting the research and development of anti-tumor drugs.

The invention discloses application of MBD3 as an intervention target in preparation of a neuroblastoma treatment medicine, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, a substance for reducing the expression level of the MBD3 gene or reducing the protein level of the MBD3 is applied to the development of a medicine for treating the neuroblastoma, and it is proved that interference on the expression of the MBD3 gene can induce the G0 / G1 phase cell cycle arrest of neuroblastoma cells and promote cell apoptosis, so that the in-vivo and in-vitro proliferation activity of the neuroblastoma cells is effectively inhibited; the small-molecule drug enbopiravidone can down-regulate the MBD3 protein level and significantly inhibit the growth of neuroblastoma cells. According to the invention, MBD3 is taken as a new target spot for treating neuroblastoma, a new direction is provided for overcoming the limitation of the existing therapy, a scientific basis is provided for developing a novel neuroblastoma treatment strategy based on MBD3 inhibition, and the application has important significance for improving the living quality and survival prognosis of high-risk children.

Herein is disclosed amphiphilic small molecules with different hydrophobic and hydrophilic fragments that show high M binding affinity to both Aβ plaques and oligomers, and selectively binding Aβ oligomers. These amphiphilic compounds can also label the Aβ species in the brain sections of transgenic AD mice, as shown by immunostaining with an Aβ antibody. Certain amphiphilic compounds were found to alleviate the Cu2+-Aβ induced toxicity in cell viability assays. Additionally, two compounds, ZY-15-MT and ZY-15-OMe, were found to disrupt the interactions between Aβ oligomers and human neuroblastoma SH-SY5Y cell membranes. These studies show compounds with amphiphilic properties that target Aβ oligomers and modulate the Aβ oligomer-cell membrane interactions can be effective as small molecule AD therapeutics. Also, the disclosed amphiphilic dicyanomethylene compounds that can emit in the near-infrared region and chelate copper can be used as early diagnostic agents for AD.

The invention relates to the technical field of medical biology, in particular to application of Skepinone-L in killing neuroblastoma cells, and finds that the Skepinone-L can specifically kill the neuroblastoma cells and significantly inhibit proliferation, migration and clone formation capabilities of the neuroblastoma cells for the first time. An action mechanism research shows that the Skepinone-L accurately targets ubiquitin specific protease 7, and is combined with a key residue through a hydrogen bond to down-regulate USP7 expression and activate a downstream apoptosis pathway. Molecular dynamics simulation proves that the compound is high in stability. The invention provides a new candidate drug with high efficiency and low toxicity for neuroblastoma, and has remarkable clinical transformation potential.

The invention discloses a method for stereoselectively synthesizing chiral bisindole with antitumor biological activity, and relates to the technical field of medicine synthesis. The chiral bisindole derivative provided by the invention has an obvious inhibition effect on the growth of human cervical cancer cells (Hela), pancreatic cancer cells (Panc-1) and human bone marrow neuroblastoma cells (Sy5y), shows good anti-tumor biological activity, and has important positive significance for promoting the research and development of anti-tumor drugs; a carbon-nitrogen bond breaking strategy is creatively adopted, a chiral phosphoric acid catalyst is used for catalysis, a nucleophilic indole C2 site stereoselective reaction is achieved, a high-quality path is provided for chiral bisindole compound synthesis, meanwhile, the method has the advantages that reaction raw materials are easy to obtain, conditions are mild, enantioselectivity, chemical selectivity and regioselectivity are high, and the method is suitable for industrial production. The atom economy is high.

The invention discloses a synthesis method of a 10-aryl evodiamine derivative in the field of new drug design and synthesis, the 10-aryl evodiamine derivative has a structural formula shown as a formula 4, and R is selected from H, alkyl, alkoxy or halogen atoms. The synthesis route is shown in the specification. Comprising the following steps: (1) taking 10-hydroxyevodiamine (1) as a raw material, and reacting the 10-hydroxyevodiamine (1) with trifluoromethanesulfonic anhydride (Tf2O) under proper conditions to obtain 10-trifluoromethanesulfonyloxy evodiamine 2; (2) reacting the compound 2 with an arylboronic acid reagent 3 under proper conditions to obtain a 10-aryl evodiamine derivative 4; wherein R of the arylboronic acid reagent 3 in the step (2) is selected from H, alkyl, alkoxy or halogen atoms. The 10-aryl evodiamine derivative 4 synthesized by the invention shows good anti-cancer activity on liver cancer cells and neuroblastoma cells, and can be applied to preparation of corresponding anti-tumor drugs.

The application discloses a tetrazole derivative, which has a structure shown in a general formula I. The application also discloses a composition containing the tetrazole derivative and application of the tetrazole derivative in preparation of a drug for preventing and resisting stroke. The inventors of the application have confirmed through multiple experiments that the compound has obvious inhibiting effect on ADP-induced platelet aggregation activity, outstanding damage protection effect on OGD / R fetal rat primary cortical neuron cells and neuron-like cells induced and differentiated from neuroblastoma cells (N2A), good anti-stroke efficacy on an animal model of focal cerebral ischemia constructed by a line plug method for temporarily blocking a middle cerebral artery and good rat oral pharmacokinetic properties. Therefore, the compound can be applied to a drug for treating and preventing stroke as a neuroprotective agent.

The present invention discloses a 2-amino-5-hydroxytetralin derivative containing a hydroxypyridone side chain, as well as its preparation and application. The target compound is obtained by using 2-amino-5-hydroxytetralin as the parent nucleus, and performing one-step condensation of a specific linker with a benzyl-protected hydroxypyridone and subsequent deprotection. Experiments have shown that at the cellular level, it has a significant anti-ferroptosis effect on RSL-3 or Erastin-induced related tumor cells (human fibrosarcoma cells HT-1080), and has a good protective effect on MPP+-induced damage-related nerve cells (human neuroblastoma cells SH-SY5Y). It also has a strong agonist effect on dopamine D2 receptors (HEK 293 cells stably transfected with human dopamine D2 receptors), and can be used to prepare corresponding anti-Parkinson's drugs. The structural formula I or II of the 2-amino-5-hydroxytetralin derivative containing a hydroxypyridone side chain is as follows: #imgabs0#

This invention relates to the field of pharmaceutical technology, specifically the application of deubiquitinase USP20 inhibitors in the preparation of drugs for treating Japanese encephalitis. This invention uses human neuroblastoma cells (SH-SY5Y) as target cells and utilizes inhibitors from a library of ubiquitination compounds to target and inhibit key enzymes in the ubiquitination pathway, aiming to identify host factors associated with Japanese encephalitis virus (JEV) infection of SH-SY5Y cells. This helps to understand the mechanism by which JEV invades the central nervous system and causes neuronal cell damage, and also provides new targets for therapeutic drugs against JEV-induced Japanese encephalitis. This invention experimentally demonstrated that deubiquitinase USP20 inhibitors have the property of inhibiting JEV infection of SH-SY5Y cells. This invention provides the application of deubiquitinase USP20 inhibitors in the preparation of drugs for treating Japanese encephalitis, offering new targets and treatment strategies for the prevention and treatment of JEV.

The invention belongs to the field of new drug design and synthesis, and relates to a synthesis method of a 10-arylamino evodiamine derivative, the 10-arylamino evodiamine derivative is shown as a formula 4, and R is selected from H, alkyl, alkoxy or fused aryl. The synthetic route comprises the following steps: (1) taking 10-hydroxyevodiamine (1) as a raw material, and reacting with trifluoromethanesulfonic anhydride (Tf2O) under proper conditions to obtain 10-trifluoromethanesulfonyloxy evodiamine 2; (2) reacting the compound 2 with an arylamine reagent 3 under proper conditions to obtain a 10-arylamine evodiamine derivative 4; wherein R of the arylamine reagent 3 in the step (2) is selected from H, alkyl, alkoxy or fused aryl. The 10-arylamino evodiamine derivative 4 synthesized by the invention shows good anti-cancer activity on liver cancer cells and neuroblastoma cells, and can be applied to preparation of corresponding anti-tumor drugs.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human neuroblastoma cells (SH-SY5Y) and human brain astroblastoma cells (U87) are taken as target cells, and the expression of the target cell part capable of exerting receptor action membrane protein is down-regulated by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting CHIKV infection of human nerve cells is found, and the purpose of blocking CHIKV infection from the source is achieved. The invention discovers that the nerve cilia protein 2 (NRP2) plays an important role in CHIKV infection SH-SY5Y and U87 cells, and the CHIKV infection can be obviously inhibited by down-regulating the expression of the NRP2. The invention provides an application of NRP2 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, arthrocele, muscular pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The invention relates to the technical field of medical biology, in particular to application of A-674563 in killing neuroblastoma cells, and finds for the first time that A-674563 can efficiently kill various neuroblastoma cells in a concentration-dependent manner, the IC50 value is as low as 0.1508 mu M, and proliferation, migration and clone formation of the neuroblastoma cells can be remarkably inhibited. The study on the mechanism of action shows that A-674563 accurately targets anaplastic lymphoma kinase (ALK) and is combined with a key residue through a hydrogen bond to down-regulate the expression of ALK protein and activate a downstream apoptosis pathway. Molecular docking and dynamics simulation prove that the two are stably and strongly combined. The invention provides an efficient novel candidate drug and a precise treatment strategy for solving the problems of limited curative effect, insufficient synergism and poor metastasis control of the existing treatment of neuroblastoma, and has a remarkable clinical transformation prospect.

The invention discloses 9-phenyl-10-alkoxy evodiamine quinazolinone with a structural formula as shown in a formula 3, wherein R is selected from alkyl or substituted alkyl. The designed and synthesized 9-phenyl-10-alkoxy evodiamine quinazolinone derivative as shown in 3 is prepared by the following steps: (1) taking 10-hydroxy evodiamine (A) as a raw material, and reacting with an alkylation reagent (RX) in the presence of a proper alkali catalyst under proper conditions to obtain 10-alkoxy evodiamine 1, 2, 3-triazole; (2) reacting the compound 1 with a bromination reagent under proper conditions to obtain 9-bromo-10-alkoxy evodiamine 2; and (3) reacting the compound 2 with an arylboronic acid reagent under proper conditions to obtain the 9-phenyl-10-alkoxy evodiamine quinazolinone derivative 3. The 9-phenyl-10-alkoxy evodiamine quinazolinone derivative synthesized by the invention shows good anti-cancer activity on liver cancer cells and neuroblastoma cells in vitro, and can be used for preparing corresponding anti-cancer drugs.

The application belongs to the technical field of biological medicine, and particularly relates to an immune liposome targeting ganglioside GD2 and mitochondria as well as a preparation method and application thereof. The application couples LX3 and thiolated daratumumab to DSPE-PEG2000 respectively to obtain DSPE-PEG2000-LX3 and DSPE-PEG2000-aGD2, and then is compounded with DSPC and cholesterol to obtain the immune liposome, which has good dispersity, excellent stability and cannot induce cytotoxicity. Cell combination and uptake analysis shows that the immune liposome can specifically target ganglioside GD2 positive tumor cells and then further reach mitochondria thereof. Compared with existing liposomes, the immune liposome provided by the application has double targeting functions of ganglioside GD2 and mitochondria, and can selectively deliver an anti-tumor drug into mitochondria of neuroblastoma cells.

The present invention provides the use of Cistancheside F or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug. In vitro experiments show that Cistancheside F has significant inhibitory activity against a variety of tumor strains, including human lung cancer cells A549, human gastric adenocarcinoma cells AGS-CAS9, human liver cancer cells SK-HEP-1, human bladder cancer cells RT112, human cervical cancer cells Hela, human prostate cancer cells PC-3, and human neuroblastoma cells SH-SY5Y. Animal experiments show that Cistancheside F has a good in vivo anti-tumor effect and has a significant therapeutic effect on a variety of tumors, such as bladder cancer and liver cancer. Cistancheside F has strong anti-tumor activity and has broad application prospects.

The application belongs to the field of biological medicine, and relates to the use of circCASC15 in the preparation of a drug for preventing and / or treating neuroblastoma and the preparation of a reagent for diagnosing neuroblastoma, wherein circCASC15 is circCASC15-1 and / or circCASC15-2, the sequence of circCASC15-1 is SEQ ID NO:1, and the sequence of circCASC15-2 is SEQ ID NO:2. By promoting the expression of circCASC15, the proliferation and migration of neuroblastoma cells are significantly inhibited. In addition, the expression of circCASC15-1 and circCASC15-2 is reduced in neuroblastoma cell lines and neuroblastoma patient tissues, and therefore the expression level of circCASC15-1 and circCASC15-2 can be used for the diagnosis of neuroblastoma.

The invention relates to the field of tumor treatment drugs, and discloses application of P5A ATPase as a target spot in preparation of neuroblastoma treatment drugs. It is found for the first time that P5A ATPase affects the expression level of LRP8 protein and endoplasmic reticulum translocation of an LRP8 signal peptide guide peptide chain, and then affects growth and proliferation of neuroblastoma cells, and a new target is provided for development of neuroblastoma treatment drugs. Besides, the invention also finds that two P5A ATPase inhibitors, namely sodium metavanadate and DCC, can inhibit endoplasmic reticulum translocation of an LRP8 signal peptide guide peptide chain and reduce the expression level of LRP8 protein, so that growth and proliferation of neuroblastoma cells are inhibited, and a new therapeutic drug is provided for neuroblastoma.

The invention discloses application of MRM2 as an intervention target in preparation of a neuroblastoma treatment medicine, and belongs to the technical field of biological medicine. The substance taking the MRM2 as the intervention target spot is a substance for down-regulating MRM2 gene expression or reducing MRM2 protein activity. It is proved that interference on MRM2 expression can induce G0 / G1 phase cell cycle arrest of neuroblastoma cells and promote cell apoptosis, and in-vivo and in-vitro proliferation activity of the neuroblastoma cells is effectively inhibited. The application of the MRM2 as the intervention target to the development of the neuroblastoma treatment medicine is proposed for the first time, a new thought is provided for breaking through the limitation of the existing therapy, and the application has important significance for improving the life quality and survival prognosis of high-risk children.

The application belongs to the field of biological medicine, and relates to the use of circTARS3 in the treatment of neuroblastoma, in particular to the use of circTARS3 in the preparation of a drug for treating neuroblastoma. The sequence of circTARS3 is SEQ ID NO:1. The expression of circTARS3 is lower in neuroblastoma cell lines and neuroblastoma patient tissues. By promoting the expression of circTARS3, the proliferation, migration and invasion ability of neuroblastoma cells can be significantly inhibited, and the drug sensitivity of other cytotoxic substances for treating neuroblastoma can be enhanced by promoting the expression of circTARS3.

This invention discloses the preparation method and uses of scutellarin 7-phosphate derivatives; belonging to the field of natural medicines and medicinal chemistry. The scutellarin 7-phosphate derivatives and their pharmaceutically acceptable salt structures described in this invention are shown in the following general formula I: By introducing a phosphate group at the 7-position, the scutellarin 7-phosphate derivatives are used in the preparation of drugs for cerebrovascular diseases. They exhibit excellent neuroprotective effects. The scutellarin phosphate derivatives of this invention have good protective activity against H2O2-induced oxidative damage to human neuroblastoma SH-SY5Y cells. Furthermore, the neuroprotective effects of some compounds are significantly stronger than those of the lead compound scutellarin.

The invention relates to the technical field of biology, and particularly discloses a carbon nano-enzyme, a preparation method thereof and application of the carbon nano-enzyme in nerve cells. The method for preparing the carbon nano enzyme comprises the following steps: (1) fully and uniformly dispersing tannic acid and urea in water; the mass ratio of the tannic acid to the urea is (2.4-2.6): 1; (2) carrying out hydrothermal reaction at the temperature of 180 to 200 DEG C, wherein the hydrothermal reaction time is 8 to 10 hours; and (3) carrying out high-speed centrifugal separation to obtain a reaction product, and directly drying. The carbon nano-enzyme not only has the anti-active nitrogen function of common carbon dots, but also has peroxidase-like activity, so that the overall oxidation resistance of the product is further enhanced. A drug delivery experiment on a human neuroblastoma cell SK-N-SH shows that the carbon nano enzyme has a certain nerve cell protection effect under the condition of low-concentration drug delivery; and under the condition of high-concentration administration, the effect of promoting apoptosis of neural cancer cells is achieved.